Related Experiment Video

Updated: Aug 4, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer

M W Pedersen1, M Meltorn, L Damstrup

  • 1Department of Radiation Biology, The Finsen Centre, National University Hospital, Copenhagen, Denmark.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 4, 2001
PubMed

Insights

Epidermal growth factor receptor variant III (EGFRvIII) mutations are common in human cancers. This review discusses EGFRvIII

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Epidermal growth factor receptor (EGFR) mutations are prevalent in various human tumors.
  • The type III EGFR mutation (EGFRvIII), characterized by a deletion in the extracellular ligand-binding domain, is the most common.
  • EGFRvIII plays a significant role in the development and progression of several cancers.

Purpose of the Study:

  • To review the current understanding of EGFRvIII's role in human cancers.
  • To detail the formation, structure, and functional significance of EGFRvIII.
  • To examine the therapeutic strategies targeting EGFRvIII.

Main Methods:

  • Literature review of preclinical and clinical studies on EGFRvIII.
  • Analysis of the molecular mechanisms underlying EGFRvIII formation and function.
  • Evaluation of targeted therapies including small molecule inhibitors, antibodies, and antisense oligonucleotides.

Main Results:

  • EGFRvIII is a common oncogenic driver in gliomas, lung, ovarian, and prostate cancers.
  • The unique structure of EGFRvIII confers constitutive activity and promotes tumor growth and survival.
  • Existing therapeutic strategies against wild-type EGFR can be adapted to target EGFRvIII.

Conclusions:

  • EGFRvIII is a critical therapeutic target in multiple human cancers.
  • Targeted therapies against EGFRvIII show promise in preclinical and clinical settings.
  • Further research into EGFRvIII targeted therapy is warranted to improve patient outcomes.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: